Intermed Consultants — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$33,069	73
2024	Research	$733,517	3
2023	Research	$342,329	4
2022	Research	$83,038	4
2019	Research	$2,074	20

Breakdown

Who paid Research payments · program years 2019–2025

Vertex Pharmaceuticals Incorporated $1,006,268 5 payments
AstraZeneca Pharmaceuticals LP $153,968 7 payments
Akebia Therapeutics Inc $33,792 92 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $987,296 3 payments
Cardiovascular Renal and Metabolism Lokelma Hyperkalemia $153,968 7 payments
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis $31,718 72 payments
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin $18,971 2 payments
Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa (FO2RWARD-2) $2,074 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.